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Purpose: The purpose of the present investigation was to formulate and evaluate microencapsulated 
glipizide produced by the emulsion – solvent evaporation method,  
Method: Microspheres were prepared using polymethacrylate polymers (Eudragit® RS 100 and RL 100) 
by solvent evaporation method and characterized for their micromeritic properties and drug loading, as 
well as by Fourier transform infrared spectroscopy (FTIR) and scanning electron microscopy. In vitro 
release studies were performed in phosphate buffer (pH 7.4).  
Result: The resulting microspheres obtained by solvent evaporation method were white and free flowing 
in nature. The mean particle size of microspheres ranged from 420 - 660 µm and the encapsulation 
efficiencies ranged from 40.27 - 86.67 %. The encapsulation efficiency was also found to be dependant 
on nature of polymer used in the formulation.  The infrared spectra confirmed the stable character of 
glipizide in the drug-loaded microspheres. Scanning electron microscopy revealed that the microspheres 
were spherical in nature. From the in vitro drug dissolution studies it was found that the sustaining effect 
of microspheres depended on the polymer concentration, amount of dispersant used and the type of 
polymer used in the formulation. The mechanism of drug release from the microspheres was found to be 
non-Fickian type.  
Conclusion: Eudragit® microspheres containing glipizide could be prepared successfully by using an 
emulsion solvent evaporation technique using polymethacrylate polymers, which will not only sustain the 
release of drug but also manage the complicacy of the diabetes in a better manner. 
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INTRODUCTION 
Microspheres have been widely accepted as a 
means to achieve oral1 and parenteral 
controlled release2 drug delivery system. The 
microsphere requires a polymeric substance 
as a carrier and a core material. Among the 
various methods developed for formulation of 
microspheres, the solvent evaporation method 
has gained much attention due to its ease of 
fabrication without compromising the activity 
of drug. In the present investigation, Eudragit® 
RS 100 and Eudragit® RS 100 in combination 
with RL 100 microsphers were used as 
encapsulation materials. Eudragit ® RS 100 
and Eudragit® RL 100 are referred to as 
ammoniomethacrylate copolymers, with the 
former having 5% functional quaternary 
ammonium groups and the latter having 10% 
functional quaternary ammonium groups. 
Eudragit® RS 100 is a water-insoluble polymer 
that is widely used as a wall material for 
sustained release microcapsules 3. This is due 
to its biocompatibility, good stability, easy 
fabrication and low cost.  The drug of choice, 
glipizide, is an effective antidiabetic drug 
particularly in Type II diabetes (Non-insulin 
dependent diabetes mellitus). It is a second-
generation sulfonylurea that actually lowers 
the blood glucose level in human by 
stimulating the pancreatic cell and thereby 
releasing the insulin. It has a short biological 
half-life of 3.4 ± 0.7 h2, 4 which make it more 
suitable to be designed as a controlled 
release formulation. The main purpose of the 
present research was to develop a controlled 
drug delivery system of glipizide for per-oral 
administration using biocompatible Eudragit® 
polymers in order to increase its biological half 
and to determine the influence of formulation 
and preparation variables on microparticle 
characteristics, such as drug incorporation 
and in vitro drug release rate. 
 
MATERIALS AND METHODS  
Materials  
Glipizide was received as a gift from M/s 
Stadmed Private Ltd, Kolkata, India. Eudragit® 
RS 100 and RL 100 were obtained from Röhm 
Pharma, GmbH, Darmstadt, Germany. All 
other reagents and solvents used were of 
pharmaceutical or analytical grade.  
Method 
Glipizide microspheres were prepared by 
solvent evaporation techniques5-7. Different 
amounts of Eudragit® RS or Eudragit® RS / RL 
combination were dissolved in 8.5 ml acetone 
separately by using a magnetic stirrer (Remi 
Equipments, Mumbai, India, model 2MIH). 
The core material, glipizide, was added to the 
polymer solution and mixed for 15 minutes, 
followed by magnesium stearate (100mg) and 
then mixed thoroughly. The resulting 
dispersion was added in a thin stream to a 
mixture of 90 ml light liquid paraffin and 10 ml 
n-hexane contained in a 250 ml beaker, while 
stirring at 700 rpm using a mechanical stirrer 
(Remi Motors, Model No.RO-123R, Mumbai, 
India.). Stirring was continued for 3 h until the 
acetone evaporated completely. The 
microspheres formed were filtered using 
Whatman no.1 filter paper. The residue was 
washed 4-5 times with 50 ml portions of n-
hexane. The product was then dried at room 
temperature for 24 hours. Formulations 
containing drug: polymer ratio 1:1.5,1:2 and 
1:3 were coded F1, F2 and F3, respectively, 
while the formulation with a Eudragit® RS: RL 
combinations of 0.9:0.1 (drug: polymer ratio1: 
3) was codeed F4. A Eudragit® RS formulation 
in a drug: polymer ratio of 1:3 and containing 
50 mg magnesium stearate coded F5 .All 
batches were prepared in triplicate.  
Micromeritic properties of beads 
The flow properties of the microspheres were 
investigated by measuring the bulk density, 
tapped density and Carr’s index1, 3. The bulk 
and tapped densities were measured in a 10 
ml graduated measuring cylinder. The sample 
contained in the measuring cylinder was 
tapped mechanically by means of constant 
velocity rotating cam. The initial bulk volume 
and final tapped volume were noted from 
which, their respective densities were 
calculated. Carr’s index was determined by 
using the following formula: 
Carr’s index =[(Tapped density-bulk density) / Tapped 
density] X 100 
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Index r2 n 
F1 89.2 420 40.3±1.16 10.3 0.997 0.651 
F2 
88.4 459 












86.7± 1.49 16.0 
* * 
Note: n = diffusion exponent and r2 = correlation coefficient related to mechanism of drug release according to 
equation, Mt / Mα= Ktn,  




Fig 1: SEM photographs of Eudragit® RS 100 microspheres, before (1) and after dissolution  
 
Fig. 2: FTIR Spectra of pure glipizide (1), Eudragit® RS 100 loaded microspheres (2), Eudragit® RS 100  
blank microsphere (3). 
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Mean particle size 
The mean particle sizes of the beads were 
determined by sieving method1,3 Microspheres 
were separated into different size fractions by 
sieving for 10 minutes using mechanical sieve 
shaker (Cuprit Electrical Co. India) containing 
standard sieves having apertures of 1000, 
710, 500, 355, 250 & 180 µm (Indian 
Pharmacopoeia, 1996). The particle size 
distribution of the microspheres for all the 
formulations was determined and mean 
particle size of microspheres was calculated 
by using the following formula.  
 
Determination of glipizide 
About 50 mg microspheres were accurately 
weighed and added to 50 ml of phosphate 
buffer (pH 7.4). The resulting mixture was 
agitated on a mechanical shaker for 24 h. The 
solution was then filtered and the drug content 
was measured at 275.2 nm 
spectrophotometrically (Systronic 2101 UV-
Visible double beam spectrophotometer, 
India) after suitable dilution.  
 
FTIR Study 
FTIR spectra of glipizide, blank microspheres 
and drug-loaded microspheres were obtained 
in KBr pellets using a Perkin-Elmer model 883 
Spectroscope in the ranges, 500 to 4000 cm-1. 
 
Scanning electron microscopy (SEM) 
A scanning electron microscope (JEOL, JSM-
6360) was used to characterize the surface 
topography of the microspheres after gold 
coating.  
Drug release behavior 8 
The in vitro dissolution studies were carried 
out in 500 ml of phosphate buffer, pH 7.4, 
maintained at 37 ± 0.5° and 100 rpm by using 
United States Pharmacopoeia basket type 
dissolution test apparatus (LABINDIA, Disso-
2000, Mumbai, India) under sink conditions. 
Accurately weighed samples of the 
microspheres were added to the dissolution 
medium and at preset time intervals, 2 ml 
aliquots were withdrawn and replaced with an 
equal volume of fresh dissolution medium. 
After suitable dilution, the samples were 
analyzed spectophotometrically at 275.2 nm. 
The concentration of glipizide in test samples 
was corrected and calculated using a 
regression equation of the calibration curve. 
The dissolution studies were carried out in 
triplicate and the mean values were plotted as 
percentage cumulative release versus time. 
Kinetics of drug release 
In order to understand the mechanism drug 
release, the first 60 % of drug release was 
fitted to the Korsmeyer-Peppas model 9. 
M t / M α =k t n 
Where M t / Mα is the fraction of the drug 
released at time, t, k is the rate constant and 
‘n’ is the release exponent. The n value is 
used to characterize different release 
mechanisms and is calculated from the slope 
of the plot of log of fraction of drug released vs 
log of time. 
RESULTS 
The resulting microspheres formulated by 
solvent evaporation method was found to be 
spherical and free flowing in nature. The mean 
particle size of microspheres ranged from 420 
- 660 µm (see Table 1). It was noticed that 
mean particle size increased with increase in 
polymer concentration and decrease in 
magnesium stearate concentration. The 
encapsulation efficiencies ranged from 40.27 - 
86.67 %. The encapsulation efficiency was 
also found to be dependant on nature of 
polymer used in the formulation. From the in 
vitro drug dissolution studies it was found that 
the sustaining effect of microspheres 
  
 
Mean Particle size  =  
Σ (Mean particle size of the fraction X weight fraction)  
        Σ Weight fraction 
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depended on the polymer concentration, 
amount of dispersant used and the type of 
polymer used in the formulation. 
DISCUSSION  
Increase of mean particle size with increase in 
polymer concentration may have occurred due 
to the fact that as polymer concentration 
increases it produces a significant increase in 
the viscosity in a fixed volume of solvent, thus 
leading to an increase of the emulsion droplet 
size and finally a higher microsphere size. 10-11 
The flow properties of the microspheres are 
expressed in terms of Carr’s Index (Table 1.). 
The Carr’s index for all formulations was less 
than 16, which indicate excellent flow 
properties and suggests that the microspheres 
can be easily handled during processing  
The encapsulation efficiency of the drug 
depended on the solubility of the drug in the 
solvent and continuous phase. An increase in 
the concentration of polymer in a fixed volume 
of organic solvent resulted in an increase in 
encapsulation efficiency12. Generally, the 
encapsulation efficiencies of the microspheres 
prepared with Eudragit® RS 100 were higher 
than those of microspheres prepared with the 
Eudragit® RS/RL combination. This can be 
attributed to the high content of the 
ammonium group in Eudragit® RL, which 
 
Fig. 3: Effect of polymer concentration on cumulative % drug release. Drug release profile from 
formulation F1  ( ), F2 ( ), F3 ( ), F4 ( ). 
 
 
Fig. 4: Effect of dispersant concentration and particle size on release of glipizide from formulation F3-50 
( ), F3 # 30 ( ) and F3 # 44( ). 
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might have facilitated the diffusion of some of 
the entrapped drug to the surrounding 
medium during formation of the microspheres. 
Higher entrapment of drug was noticed when 
a lower concentration of magnesium stearate 
was used. This may be due to the formation of 
large-size microspheres at lower magnesium 
stearate levels, which provided less surface 
area for drug escape to the external 
processing medium. 
Scanning electron microscopic photographs of 
microspheres are shown in Fig. 1. The surface 
of the microspheres appeared spherical but 
rough. The microsphere were not agregated. 
Glipizide showed prominent peaks at 1651, 
2943, 3354, 1529 and 1689 due to the 
presence of C = N aliphatic group, C-H2  
aliphatic, N-H stretching of NH2, C-H  aliphatic 
and C=O stretching (Fig. 2). The same peaks 
were also observed in the formulation 
indicating the stable nature of the drug during 
encapsulation. 
Fig. 3 shows that the release of glipizide from 
the microspheres and it illustrates that the rate 
of drug release from the microspheres 
depended on the polymer concentration and 
the type of polymer used. The decrease in 
release rate with increasing content of the 
polymer can be explained by a decreased 
amount of drug present close to the surface 
and also by the fact that the amount of 
uncoated drug decreases with increase in 
polymer concentration13. When Eudragit® RL 
was used in combination with Eudragit RS, the 
drug released at a faster rate compared to 
Eudragit® RS alone. This is due to the fact that 
the amount of quaternary ammonium groups of 
Eudragit® RS is lower than that of Eudragit RL, 
which renders Eudragit® RS is less 
permeable14. The effect of magnesium stearate 
on drug release rate is shown in Fig. 4 .The 
faster drug release dispersing agent 
concentration rose may be due to decrease in 
particle size, which provided a larger surface 
for drug release. The effect of particle size on 
the drug release was also studied using 
microspheres of different size fractions (355 
and 500 µm, respectively) as shown in Fig. 4. 
The release profile was in line with the theory 
of the effect of the particle size on dissolution 
rate 1. As microsphere size decreased, the 
drug release increased as result of higher 
surface area. 
In order to determine the mechanism of drug 
release the data obtained were fitted to the 
Korsemeyer-Peppas model in order to 
determine the ‘n’ value, which describes the 
drug release mechanism9. The ‘n’ value of all 
the formulations was between 0.5 and 1 
indicating that the mechanism of drug release 
was non-Fickian type diffusion.  
 
CONCLUSION 
Eudragit® microspheres containing glipizide 
can be prepared successfully by using an 
emulsion solvent evaporation technique. The 
surface structure of the microspheres was 
spherical and rough. The encapsulation 
efficiencies were over 40 % and the mean 
size was in the range of 420 - 660 µm. The 
release rate of Eudragit® RS 100 
microspheres was much slower than that than 
those prepared with the combination of 
Eudragit® RS/RL 100. The release pattern of 
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